# DESCRIPTION

## RELATED PATENT APPLICATION

- claim priority to European Patent Application

## BACKGROUND OF THE INVENTION

- introduce osteosarcoma
- describe limitations of heparin and heparan sulfate
- discuss sulfated oligosaccharides and polysaccharides
- motivate need for new therapeutic strategies

## SUMMARY OF THE INVENTION

- introduce low-molecular-weight over-sulfated polysaccharide
- describe in vitro experiments on osteosarcoma cell lines
- describe in vivo experiments on primary malignant bone tumor growth
- summarize anti-metastatic properties of GYS15

## Definitions

- define subject
- define cancer
- define aggressive and invasive
- define metastasis
- define inhibit
- define treatment, pharmaceutical composition, and therapeutically effective amount

## DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS

- describe GYS15, a low molecular weight over-sulfated exopolysaccharide derivative

### I—Low Molecular Weight Over-Sulfated Exopolysaccharide Derivatives

- relate GYS15 to marine native exopolysaccharide (EPS) from Alteromonas genus
- describe processes for obtaining low-molecular-weight over-sulfated polysaccharide derivatives
- outline method for preparing GYS15, including free-radical depolymerization and sulfation steps
- detail free-radical depolymerization step, including reaction conditions and catalysts
- describe optional reduction step to stabilize polysaccharide chains
- outline methods for eliminating metal catalyst and recovering polysaccharide derivatives
- describe sulfation step, including choice of sulfation agents and reaction conditions
- detail methods for recovering and purifying sulfated polysaccharide derivatives
- describe final product, GYS15, including its molecular weight and polydispersity index
- outline methods for characterizing GYS15, including measurement of polydispersity index

### II—Uses of the Low Molecular Weight OS-EPS Derivative

- introduce therapeutic applications of GYS15
- describe prevention of metastases formation as a therapeutic application
- outline methods of prevention, including administration of GYS15 or pharmaceutical composition
- describe various routes of administration, including aerosol, parenteral, oral, and topical
- detail various cancers that may be treated with GYS15
- describe effective amounts and dosages of GYS15
- outline methods for monitoring treatment effects
- describe combination therapy with additional therapeutic agents or procedures
- detail various anti-cancer agents that may be used in combination with GYS15

### III—Pharmaceutical Compositions

- introduce pharmaceutical compositions
- describe GYS15 and pharmaceutically acceptable carriers
- formulate injectable preparations
- describe sterile injectable solutions and suspensions
- formulate liquid dosage forms for oral administration
- describe solid dosage forms for oral administration
- formulate capsules, tablets, pills, powders, and granules
- describe topical administration
- formulate transdermal devices
- describe suppository formulations
- introduce additional biologically active agents
- describe pharmaceutical packs or kits
- outline contents of pharmaceutical packs or kits

## EXAMPLES

- describe examples of making and practicing the present invention

### Materials and Methods

- produce and characterize bacterial GY785 exopolysaccharide (EPS)
- prepare and characterize low molecular weight (LMW) over-sulfated (OS) EPS derivatives
- perform proliferation assays
- perform migration assays
- perform invasion assays
- perform cell cycle analysis and matrix metalloproteinase expression analysis

### Osteosarcoma Mouse Model

- describe osteosarcoma mouse model

### Lung Metastasis Mouse Model

- describe lung metastasis mouse model

### Statistical Analysis

- describe statistical analysis of results

### Results

- describe in vitro effect of LMW OS-EPS on osteosarcoma cell lines
- describe cell migration results
- describe cell invasion results
- describe cell cycle results
- describe matrix metalloproteinase expression results
- describe in vivo studies on primary malignant bone tumor growth
- describe in vivo studies on lung metastases model

## CONCLUSIONS

- summarize therapeutic interest of LMW OS-EPSs

